Should You Buy Innoviva Inc (INVA) Stock on Monday?

Innoviva Inc (INVA) stock is up 4.40% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Innoviva Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INVA!

See Full INVA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With INVA Stock Today?

Innoviva Inc (INVA) stock is higher by 0.7% while the S&P 500 is lower by -0.2% as of 12:05 PM on Monday, Mar 25. INVA is up $0.10 from the previous closing price of $15.09 on volume of 101,054 shares. Over the past year the S&P 500 is up 31.33% while INVA is up 33.57%. INVA earned $2.07 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.34.

More About Innoviva Inc

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Click Here to get the full Stock Report for Innoviva Inc stock.